Kamada Ltd stock (IL0010952647): shares stabilize after recent results as investors eye valuation metrics

Kamada Ltd shares on Nasdaq in the United States are trading steadily after the latest quarterly update, as investors reassess the Israeli plasma-focused biopharmaceutical group’s earnings profile and valuation multiples.

Kamada Ltd shares were little changed in Thursday trading on Nasdaq, with the Israel-based plasma-derived therapies specialist holding broadly steady after its recent quarterly earnings release gave investors fresh insight into revenue trends and margins for 2025, according to Nasdaq data as of 05/28/2026.

The biopharmaceutical group, headquartered in Rehovot, Israel and listed on Nasdaq under the ticker KMDA, remains closely watched in its home market and by U.S. healthcare investors given its focus on specialty plasma-derived and protein-based treatments for serious medical conditions.

Following the latest published results, the stock has been consolidating in a narrow range as the market digests updated sales figures from Kamada’s immunoglobulin and specialty plasma product portfolio as well as commentary about demand in core markets such as the United States and Europe, according to the company’s investor relations materials and recent earnings communication.

The price stability in recent sessions contrasts with the volatility seen around earlier earnings dates, when changes in guidance or product-mix commentary often led to sharper swings in the share price, based on trading data compiled by Nasdaq and other market platforms that track KMDA.

From a home-country perspective, Kamada remains one of the better-known Israeli biopharmaceutical names among international investors, and its Nasdaq listing in the United States places the company within the broader U.S. healthcare and biotech universe rather than on the Tel Aviv Stock Exchange, which also shapes how global funds and benchmarks approach the name.

For investors in Germany who follow international healthcare stocks, Kamada is additionally available via off-exchange trading platforms such as Tradegate, where the shares typically track the primary Nasdaq quote in euro terms, providing an access point for European private investors who prefer to trade during Central European hours.

The stock’s recent behavior reflects not only company-specific developments but also the broader sentiment toward smaller-cap biopharmaceutical names exposed to plasma-derived therapies, a niche that can be influenced by reimbursement decisions, regulatory developments, and competition from larger plasma players in the United States and Europe.

While the latest quarter’s headline figures did not trigger a pronounced re-rating in the equity market immediately, they did contribute to a clearer picture of Kamada’s revenue trajectory for the current financial year and the associated profitability profile across its key therapeutic areas, as highlighted in the firm’s most recent investor presentation.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: KMDA
• Sector/industry: Biopharmaceuticals, plasma-derived and protein-based therapies
• Headquarters/country: Rehovot, Israel
• Core markets: United States, Europe, Israel
• Key revenue drivers: Immunoglobulin and specialty plasma-derived products for rare and serious diseases
• Home exchange/listing venue: Nasdaq (KMDA)
• Trading currency: USD

Kamada Ltd: core business model

Kamada focuses on developing, manufacturing, and marketing plasma-derived and other protein-based therapies that address serious and often rare medical conditions, with revenue concentrated in specialty immunoglobulin and plasma product franchises sold in key markets such as the United States, Europe, and Israel.

Valuation metrics and multiples for Kamada Ltd

With earnings and cash flow data from the latest reported quarter now in the market, valuation discussions around Kamada increasingly center on how its current market capitalization and enterprise value compare to trailing and forward-looking profit measures, including metrics such as the price-to-earnings ratio and enterprise value to EBITDA, as calculated from the company’s financial statements and consensus estimates on financial data platforms.

Relative to larger plasma-focused peers, sector data indicate that investors often assign a discount or premium depending on Kamada’s growth visibility, product concentration, and profitability profile, and the latest quarterly figures provide additional inputs for assessing whether the current multiples adequately reflect the company’s positioning within the global plasma-derived therapeutics segment.

Conclusion

The current period of share price consolidation for Kamada on Nasdaq follows the company’s recent quarterly report, which updated the market on revenue performance and margins in its plasma-derived therapies portfolio.

Against this backdrop, valuation metrics such as earnings and cash flow-based multiples are now in sharper focus as investors weigh the company’s growth profile and competitive positioning in the plasma-derived therapeutics niche without a strong immediate directional move in the share price.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.